Top Rated Speakers Include:

Realising the Commercial Potential of Implementing Pharmaceutical Co-Crystals into Your R&D Strategy

Pharmaceutical Co-Crystals are now being recognised as an attractive alternative route for solid state development. Through integration of a co-former partner into the crystal lattice, it is possible to manipulate the physico-chemical characteristics of the API thus enhancing properties such as solubility, dissolution rate, stability and bioavailability, which are integral to the effectiveness and success of future medicines. At present, achieving scale up of co-crystal production while maintaining the physico-chemical advantages which they afford is a major challenge in the pharmaceutical arena.

For that reason, Pharmaceutical Co-Crystals 2010 will explore the results and knowledge acquired over the years on perfecting the art of co-crystal formation and how best to apply it at both the laboratory and manufacturing scale, with the ultimate aim of realising the commercial potential of co-crystals in pharmaceutical drugs.


Amorphous-Pharmaceutical-Materials-2010

Topics from leading pharmaceutical and academic professionals in the field will include:

  • Utilise the advantages of solid state NMR (SSNMR) for the identification and characterisation of pharmaceutical co-crystals with Dr Tran Pham, GlaxoSmithKline
  • Explore the thermodynamic stability during co-crystal formation and understanding how thermodynamics inform the design of slurry experiments on co-crystals: insights from Dr Richard Schartman, Bristol Myers Squibb
  • Predict co-crystal-solution phase behaviour and guide co-crystal selection without the time and material consuming requirements of traditional methods: approaches from Associate Professor, Naír Rodríguez-Hornedo, University of Michigan
  • Determine the relative contributions of Van der Waals versus hydrogen bond forces to the heat of formation values during co-crystal formation with Dr Mark Oliveira, Alkermes
  • Learn practical tools for co-crystal development and novel approaches to co-crystal design and scale up to realise co-crystals potential in an industrial environment by leveraging phase behaviour early for condition screening: methods from Dr Adam O’neil, Vertex Pharmaceuticals
  • Achieve consistent production of co-crystals of the purity, form, and size set in the specification, with high yield through extensive scale up activities for crystallisation, filtration, drying, and milling operations using PAT tools: insights from Dr Peter Karpinski, Novartis

To see more details about these talks and the rest of the outstanding sessions simply download the brochure

Testimonials

I learned a lot. This will add to my research
Dr Sumod George, Lulea Technical University, Sweden
Very good mix of science & applications. Very useful for science, information & networking
Ashwini Nangia, University of Hyderabad, India
The event has been valuable and informative
Dr Anil Kumar, Institute of Life Sciences
Good panel of speakers
Rome Sandrine, UCB Pharma SA
Overall very good. I have learnt about new processes which will be very valuable in future works
Matt Tandy, SAFC Pharorphix Ltd
A high standard of speakers present. Very good at giving me an idea of the co-crystal landscape in preparation, application & legal fields
Noel Hamill, Almac Sciences
Session Sponsors Featured Exhibitor
_spex crysforma
Media Partners
Media-Partners

[ Register Now ]